The Court of Appeal (Floyd LJ, Kitchin LJ and Longmore LJ) held that there was no issue of principle which prevented the courts from exercising their discretion to grant declarations of the type postulated in Arrow Generics Ltd (i.e. declarations that a product was old or obvious in patent law terms at a particular date)…

On 3 March 2017, the English Patents Court (Henry Carr J) issued a decision (here) in the joined claims filed by Fujifilm Kyowa Biologics (FKB) and Samsung Bioepis/Biogen (S/B) against AbbVie Biotechnology Limited (AbbVie) for so-called Arrow declarations in relation to dosage regimes of adalimumab (sold by AbbVie under the brand name Humira) for the…